The US Centers for Disease Control and Prevention (CDC) has issued a provisional recommendation for the use of Pfizer’s (NYSE: PFE) bivalent respiratory syncytial virus (RSV) vaccine, Abrysvo, as a seasonal maternal immunization strategy. This measure aims to prevent RSV lower respiratory tract infection in infants, a significant cause of infant illness and hospitalization.
RSV Prevention and Maternal Immunization
According to Fineline Info & Tech data, Abrysvo was approved for this specific indication last month, marking a significant step in the prevention of RSV infections in infants. The vaccine’s provisional recommendation by the CDC highlights the importance of maternal immunization in protecting vulnerable infants from RSV, which can lead to severe respiratory illnesses.
Significance of the Recommendation
The provisional recommendation by the CDC underscores the role of vaccination in public health strategies to reduce the burden of RSV, particularly in high-risk populations such as infants. By targeting maternal immunization, the aim is to provide passive immunity to infants during their first months of life, a critical period for RSV protection.-Fineline Info & Tech
